Alzheimer's disease(AD)is a neurodegenerative disease with highly heterogeneous pathological and clinical manifesta-tions,and it is the most common cause of dementia.This heterogeneity poses challenges for diagnosis,treatment,and evaluating novel pharmacological efficacy.This review summarizes the latest progress in the major clinical subtypes of AD based on clinical manifesta-tions,genetic,and pathological features.Early-onset and late-onset AD clinical subtypes may share the same symptoms but differ in etiology,age of onset,mode of presentation,disease progression,and associated comorbidities.Typical and atypical AD differ signifi-cantly in clinical manifestations,pathological features,and diagnostic criteria.Research on AD subtypes based on imaging and omics data has also made considerable progress.This review also outlines the molecular pathological heterogeneity of AD.A deep understand-ing of these heterogeneities is crucial for diagnosis,the formulation of pharmacological treatment strategies,and clinical management.

Biological pharmaceutics is not only the important basic course in medicine,biotechnology,but also the course of combination of theory and practice.Experiment plays an important role in the teaching system of biological pharmaceutics.According to the characteristics of biopharmaceutical and the demand for talent cultivation,we have made some adjustments from the basic process of genetic engineering drug preparation such as rearranging biopharmaceutical experimental classes to form a systemic experiment content,increasing the experiment lesson,innovatively making the students participant in the experiment preparation,and opening the laboratory and improve the method of experiment examination.It has been proved that this teaching reform can improve the teaching quality of experimental class,and has valuable demonstration significance and reference value to the quality education and experimental teaching reform.